Evidence-based clinical pathways might be able to reduce overall spending on cancer care without compromising quality. According to a new study, an oncology pathways program could save about 15% on ...
Dynamic clinical pathways are essential to keep pace with rapid advancements in oncology treatments and FDA approvals. Inclusive participation and effective communication are vital for pathway ...
Protocol-Stipulated Dose Modification to Manage Chemotherapy-Induced Peripheral Neuropathy in Children, Adolescents, and Young Adults With High-Risk Hodgkin Lymphoma We conducted a retrospective ...
Cancer cells survive therapy by dynamically rewiring their metabolism in response to nutrient availability, ...
Gastric cancer cells can activate KRAS-driven signals, enabling autonomous tumor growth by producing their own WNT proteins. New research reveals how gastric cancer cells exploit WNT signaling for ...
The FDA-approved drug combination specifically targets low-grade serous ovarian cancer, which primarily affects younger women ...
A protein once thought to simply help cancer cells avoid death turns out to do much more. MCL1 actively drives cancer ...
Datopotamab deruxtecan received FDA approval for HR+/HER2– breast cancer, improving progression-free survival and overall ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback